marketcaparena

Parabilis Medicines, Inc.

PBLS

Overview

Share price

Daily closing price. The header shows the latest close, the market cap at that close and the change over the selected range. Hover or tap the chart to read any day.
$30.28
−$1.32 (−4.18%)since Jun 10, 2026
Market cap
$3.74B
At close
Oct 2, 2026

Share price vs index

Parabilis Medicines's share price and the index, each as its percentage change since the first day of the selected range. The shading shows the gap: green while Parabilis Medicines is ahead, orange while it is behind. The values at the end are each one's change over the range.

About Parabilis Medicines

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

parabilismed.com ↗

Employees
145
Business address
CAMBRIDGE, MA
Fiscal year ends
December 31
Listed
Nasdaq · PBLS

Income statement

Revenue

Q2 26
Full year
Quarter
Revenue each quarter. The figure at the top of each column is growth against the same period a year earlier. Choose quarterly or annual; the arrows step a year earlier or later.
Revenue

Revenue, gross profit and net income

Q2 26
Full year
Quarter
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Income statement

Q2 26
Full year
Quarter
How revenue becomes net income in the chosen year or quarter. Solid bars are totals; hatched bars are the costs taken off between them.
TotalSubtracted

Operating leverage

Q1 26
Full year
Quarter
Revenue growth against operating expense growth, each against the same quarter a year earlier. While revenue grows faster than opex, each extra dollar of sales keeps more profit.

Cash flow

Operating and free cash flow

Q1 26
Full year
Quarter
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Free cash flow

Q1 26
Full year
Quarter
Operating cash flow minus capital expenditure. The figure at the top of each column is growth against the same period a year earlier.
Free cash flow

Capital allocation

Q1 26
Full year
Quarter
Operating cash flow above zero; what it was spent on below: capital expenditure, dividends and buybacks.

Balance sheet

Assets, liabilities and equity

Q2 26
Full year
Quarter
The balance sheet at the end of the chosen year or quarter. What the company owns on the left, against what it owes and what belongs to shareholders on the right. Both columns add up to total assets.

Net cash

Q2 26
Full year
Quarter
Cash and short-term investments minus total debt at each quarter end. Below zero, the company owes more than it holds.
Net cashNet debt

War chest

Q2 26
Full year
Quarter
Cash and short-term investments held at each quarter end. The figure at the top of each column is the total.